The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
EU Panel Recommends Olaparib Tablets for Ovarian Cancer, Regardless of BRCA Status
February 24th 2018The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer
February 23rd 2018European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.
Concomitant Chemoradiation Remains Standard in Locally Advanced Cervical Cancer
February 19th 2018Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.